Decoy Therapeutics Inc.
For the period ended Mar 31, 2026. Filed May 8, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 8, 2026
DCOY$1.11+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating activities | ||
| Net loss | $(2,224,628) | $(1,709,533) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 5,924 | 1,106 |
| Equity-based compensation | 213,044 | 33,534 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (261,821) | 46,328 |
| Accounts payable | (4,556) | 254,645 |
| Accrued expenses and other | (617,292) | 192,206 |
| Net cash used in operating activities | (2,889,329) | (1,181,714) |
| Financing activities | ||
| Proceeds from issuance of equity securities, net | — | 655,202 |
| Payments on note payable | — | (109,636) |
| Net cash provided by financing activities | — | 545,566 |
| Net decrease in cash | (2,889,329) | (636,148) |
| Cash, cash equivalents, and restricted cash at beginning of period | 10,709,937 | 2,434,528 |
| Cash, cash equivalents, and restricted cash at end of period | $7,820,608 | $1,798,380 |
| Supplemental cash flow information | ||
| Cash paid for interest | $8,476 | $4,094 |
| Accrued issuance costs for public offering | $— | $429,032 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.